[1] DE JONG OG, KOOIJMANS SAA, MURPHY DE, et al. Drug delivery with extracellular vesicles: from imagination to innovation. Acc Chem Res. 2019;52(7):1761-1770.
[2] De Jong OG, Van Balkom BW, Schiffelers RM, et al. Extracellular vesicles: potential roles in regenerative medicine. Front Immunol. 2014;5:608.
[3] 张阳.慢病毒载体的研究进展[J].福建医科大学学报,2014,48(6):407-410.
[4] 吴清胜,李媛媛.腺病毒载体的研究及应用进展[J].国际生物制品学杂志, 2021,44(6):353-360.
[5] 翟贯星,傅卫辉,徐建青,等.腺相关病毒载体优化的研究进展[J].复旦学报(医学版),2021,48(6):827-833.
[6] RAYAMAJHI S, NGUYEN TDT, MARASINI R, et al. Macrophage-derived exosome-mimetic hybrid vesicles for tumortargeted drug delivery. Acta Biomater. 2019;94: 482-494.
[7] 董丽娜,蔡璐璐,赵明明,等.生物大分子载体在肿瘤纳米靶向药物研发中的应用研究进展[J].山东医药,2019,59(35):83-87.
[8] 翟宏强,丁维明,李桂玲.聚合物胶束注射给药系统的研究进展[J].中国医药生物技术,2015,10(5):441-447.
[9] 侯天宇,赖芳芳,李青山.载药纳米聚合物研究进展[J].江西化工,2011(2): 12-15.
[10] SILVA AK, LUCIANI N, GAZEAU F, et al. Combining magnetic nanoparticles with cell derived microvesicles for drug loading and targeting. Nanomedicine. 2015;11(3):645-55.
[11] HERRMANN IK, WOOD MJA, FUHRMANN G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16:748-759.
[12] HARDING C, HEUSER J, STAHL P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 1983;97:329-39.
[13] PAN BT, JOHNSTONE RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983; 33:967-978.
[14] JOHNSTONE RM, ADAM M, HAMMOND JR, et al. Turbide, Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412-9420.
[15] RAPOSO G, NIJMAN HW, STOORVOGRL W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996;183:1161-1172.
[16] CAO HQ, WANG H, HE XY, et al. Bioengineered macrophages can responsively transform into nanovesicles to target lung metastasis. Nano Lett. 2018;18:4762-4770.
[17] WEI DG, ZHAN WX, GAO Y, et al. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2021;31:157-177.
[18] SCHIAPPARELLI LM, SHARMA P, HE HY, et al. Proteomic screen reveals diverse protein transport between connected neurons in the visual system. Cell Rep. 2022;38:110287.
[19] SUN D, ZHUANG X, XIANG X, et al. A novel nanoparticle drug delivery system: theanti-inflammatory activity of curcumin is enhanced when encapsulated inexosomes. Mol Ther. 2010;18(9):1606-1614.
[20] WALKER S, BUSATTO S, PHAM A, et al. Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics. 2019;9(26):8001-8017.
[21] O’LOUGHLIN AJ, MAGER I, DE JONG OG, et al. Functional delivery of lipid-conjugated siRNA by extracellular Vesicles. Mol Ther. 2017;25:1580-1587.
[22] WANG J, LEE CJ, DECI MB, et al. MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair. Nanomedicine. 2020;27:102201.
[23] SATO YT, UMEZAKI K, SAWADA S, et al. Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep. 2016;6:21933.
[24] OSKOUIE MN, AGHILI MOGHADDAM NS, BUTLER AE, et al. Therapeutic use of curcumin-encapsulated and curcumin-primed exosomes. J Cell Physiol. 2019; 234(6):8182-8191.
[25] KANG JY, KIM H, MUN D, et al. Co-delivery of curcumin and miRNA-144-3p using heart-targeted extracellular vesicles enhances the therapeutic efficacy for myocardial infarction. J Control Release. 2021;331:62-73.
[26] HANEY MJ, KlYACHKO NL, ZhAO Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release. 2015;207:18-30.
[27] JAMUR MC, OLIVER C. Permeabilization of cell membranes. Methods Mol Biol. 2010;588:63-66.
[28] FUHRMANN G, SERIO A, MAZO M, et al. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2015;205:35-44.
[29] YI G, SON J, YOO J, et al. Application of click chemistry in nanoparticle modification and its targeted delivery. Biomater Res. 2018;22:13.
[30] HOOD JL. Post isolation modification of exosomes for nanomedicine applications. Nanomedicine (Lond). 2016;11:1745-1756.
[31] SINGH A, TRIVEDI P, JAIN NK. Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46:274-283.
[32] PIFFOUX M, SILVA AKA, WILHELM C, et al. Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems. ACS Nano. 2018;12(7):6830-6842.
[33] ESCUDE MARTINEZ DE CASTILLA P, TONG L, HUANG C, et al. Extracellular vesicles as a drug delivery system: a systematic review of preclinical studies. Adv Drug Deliv Rev. 2021;175:113801.
[34] KOOIJMANS SAA, FLIERVOET LAL, VAN DER MEEL R, et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release. 2016;224:77-85.
[35] WAN Y, WANG L, ZHU C, et al, Aptamer-conjugated extracellular nanovesicles for targeted drug delivery. Cancer Res. 2018;78(3):798-808.
[36] KIM MS, HANEY MJ, ZHAO Y, et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2018;14(1):195-204.
[37] DAMS ET, LAVERMAN P, OYEN WJ, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292(3):1071-1079.
[38] ISHIDA T, MAEDA R, ICHIHARA M, et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88(1):35-42.
[39] FAN J, PAN J, ZHANG X, et al. A peptide derived from the N-terminus of charged multivesicular body protein 6 (CHMP6) promotes the secretion of gene editing proteins via small extracellular vesicle production. Bioengineered. 2022;13(3):4702-4716.
[40] KIM H, MUN D, KANG JY, et al. Improved cardiac-specific delivery of RAGE siRNA within small extracellular vesicles engineered to express intense cardiac targeting peptide attenuates myocarditis. Mol Ther Nucleic Acids. 2021;24:1024-1032.
[41] LIU B, LEE BW, NAKANISHI K, et al. Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells. Nat Biomed Eng. 2018; 2(5):293-303.
[42] HEALLEN TR, MARTIN JF. Heart repair via cardiomyocyte-secreted vesicles. Nat Biomed Eng, 2018;2:271-272.
[43] LE BRAS A. Exosome-based therapy to repair the injured heart. Nat Rev Cardiol. 2018;15(7):382.
[44] WEI Z, CHEN Z, ZHAO Y, et al. Mononuclear phagocyte system blockade using extracellular vesicles modified with CD47 on membrane surface for myocardial infarction reperfusion injury treatment. Biomaterials. 2021;275:121000.
[45] MURPHY DE, DE TONG OG, BROUWER M, et al. Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med. 2019;51(3):1-12.
[46] 韩超珊. MiR--675和水凝胶对间充质干细胞外泌体的改造和应用研究[D].苏州:苏州大学,2019.
[47] SONG Y, ZHANG C, ZHANG J, et al. Localized injection of miRNA-21-enriched extracellular vesicles effectively restores cardiac function after myocardial infarction. Theranostics. 2019;9;2346-2360.
[48] FU DL, JIANG H, LI C, et al. MicroRNA-338 in MSCs-derived exosomes inhibits cardiomyocyte apoptosis in myocardial infarction. Eur Rev Med Pharmacol Sci. 2020;24;10107-10117.
[49] LI Y, YANG R, GUO B, et al. Exosomal miR-301 derived from mesenchymal stem cells protects myocardial infarction by inhibiting myocardial autophagy. Biochem Biophys Res Commun. 2019;514:323-328.
[50] WEI Z, QIAO S, ZHAO J, et al. miRNA-181a over-expression in mesenchymal stem cell-derived exosomes inflfluenced inflflammatory response after myocardial ischemia-reperfusion injury. Life Sci. 2019; 232:116632.
[51] DENG S, ZHOU X, Ge Z, et al. Exosomes from adipose-derived mesenchymal stem cells ameliorate cardiac damage after myocardial infarction by activating S1P/SK1/S1PR1 signaling and promoting macrophage M2 polarization. Int J Biochem Cell Biol. 2019;114:105564.
[52] YU DW, GE PP, LIU AL, et al. HSP20-mediated cardiomyocyte exosomes improve cardiac function in mice with myocardial infarction by activating Akt signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23(11):4873-4881.
[53] ZHANG N, SONG Y, HUANG ZC, et al. Monocyte mimics improve mesenchymal stem cell-derived extracellular vesicle homing in a mouse MI/RI model. Biomaterials. 2020;255:120168.
[54] LI Q, HUANG Z, WANG Q, et al. Targeted immunomodulation therapy for cardiac repair by platelet membrane engineering extracellular vesicles via hitching peripheral monocytes. Biomaterials. 202;284:121529.
[55] HUANG K, OZPINAR EW, SU T, et al. An off-the-shelf artifificial cardiac patch improves cardiac repair after myocardial infarction in rats and pigs. Sci Transl Med. 2020;12(538):eaat9683.
[56] GAO L, KUPFER ME, JUNG JP, et al. Myocardial tissue engineering with cells derived from humaninduced pluripotent stem cells and a native-like, high-resolution, 3- dimensionally printed scaffold. Circ Res. 2017;120(8):1318-1325.
[57] TANG J, VANDERGRIFF A, WANG Z, et al. A regenerative cardiac patch formed by spray painting of biomaterials onto the heart. Tissue Eng Part C. 2017;23(3):146-155.
[58] ZHU D, LI Z, HUANG K, et al. Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair. Nat Commun. 2021;12(1):1412.
[59] ZHANG Y, CAI Z, SHEN Y, et al. Hydrogel-load exosomes derived from dendritic cells improve cardiac function via Treg cells and the polarization of macrophages following myocardial infarction. J Nanobiotechnol. 2021;19(1):271.
[60] MENTKOWSKI KI, LANG JK. Exosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo. Sci Rep. 2019; 9(1):10041.
[61] VANDERGRIFF A, HUANG K, SHEN D, et al. Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide. Theranostics. 018;8(7):1869-1878.
[62] CIULLO A, BIEMMI V, MILANO G, et al. Exosomal expression of CXCR4 targets cardioprotective vesicles to myocardial infarction and improves outcome after systemic administration. Int J Mol Sci. 2019;20(3):468.
[63] MAO S, ZHAO J, ZHANG ZJ, et al. MiR-183-5p overexpression in bone mesenchymal stem cell-derived exosomes protects against myocardial ischemia/reperfusion injury by targeting FOXO1. Immunobiology. 2022;227(3):152204.
[64] WANG Y, DING N, GUAN G, et al. Rapid delivery of Hsa-miR-590-3p using targeted exosomes to treat acute myocardial infarction through regulation of the cell cycle. J Biomed Nanotechnol. 2018;14:968-977
[65] CHEN W, LI L, WANG J, et al. Extracellular vesicle YsRNA in atherosclerosis. Clin Chim Acta. 2021;517:15-22.
[66] PERDOMO L, VIDAL-GOMEZ X, SOLETI R, et al. Large Extracellular vesicle-associated rap1 accumulates in atherosclerotic plaques, correlates with vascular risks and is involved in atherosclerosis. Circ Res. 2020;127(6):747-760.
[67] WU GH, ZHANG JF, ZHAO QR, et al. molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment. Angew Chem Int Ed Engl. 2020;59:4068-4074.
[68] PAPE AC, BAKKER MH, TSENG CC, et al. An injectable and drug-loaded supramolecular hydrogel for local catheter injection into the pig heart. J Vis Exp. 2015;(100):e52450.
[69] CHENG G, ZHU D, HUANG K, et al. Minimally invasive delivery of a hydrogel-based exosome patch to prevent heart failure. J Mol Cell Cardiol. 2022;169:113-121.
[70] SINDI HA, RUSSOMANNO G, SATTA S, et al. Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nat Commun. 2020;11:1185.
[71] LIU LN, ZHANG HR, MAO HY, et al. Exosomal miR-320d derived from adipose tissue-derived MSCs inhibits apoptosis in cardiomyocytes with atrial fibrillation (AF). Artif Cells Nanomed Biotechnol. 2019;47:3976-3984.
[72] KIM H, YUN N, MUN D, et al. Cardiac-specific delivery by cardiac tissue-targeting peptide-expressing exosomes. Biochem Biophys Res Commun. 2018;499(4):803-808.
[73] TIAN Y, Li S, SONG J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383-2390.
[74] SCHINDLER C, COLLISON A, MATTHEWS C, et al. Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency. PLoS One. 2019;14(3):e0214545.
[75] SUN W, ZHAO P, ZHOU Y, et al. Ultrasound targeted microbubble destruction assisted exosomal delivery of miR-21 protects the heart from chemotherapy associated cardiotoxicity. Biochem Biophys Res Commun. 2020;532(1):60-67.
[76] WAN Z, ZHAO L, LU F, et al. Mononuclear phagocyte system blockade improves therapeutic exosome delivery to the myocardium. Theranostics. 2020;10(1):218-230.
[77] LASSER C, ELDH M, LOTVALL J. Isolation and characterization of RNA-containing exosomes. J Vis Exp. 2012;(59):e3037.
[78] 贺继刚,韩金秀,撒亚莲,等.过表达IDO骨髓间充质干细胞分泌外泌体改善移植心脏存活[J].安徽医科大学学报,2018,53(9):1383-1387.
[79] GHARPURE KM, WU SY, LI C, et al. Nanotechnology: future of oncotherapy. Clin Cancer Res. 2015;21(14):3121-3130.
[80] BORRELLI DA, YANKSON K, SHUKLA N, et al. Extracellular vesicle therapeutics for liver disease. J Control Release. 2018;273:86-98.
[81] WIKLANDER OP, NORDIN JZ, O’LOUGHLIN A, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. Journal of extracellular vesicles. 2015;4:26316.
[82] SUH A, PHAM A, CRESS MJ, et al. Adipose-derived cellular and cell-derived regenerative therapies in dermatology and aesthetic rejuvenation. Ageing Res Rev. 2019;54:100933.
[83] AMIRI A, BAGHERIFAR R, ANSARI DEZFOULI E, et al. Exosomes as bio-inspired nanocarriers for RNA delivery:preparation and applications. J Transl Med. 2022;20(1):125. |